INPHARMA
The Association of Pharmaceutical Companies «Innovative Pharma» (InPharma) brings together major pharmaceutical companies that actively invest in research and development and are counted among the top 20 global pharmaceutical producers.
ASSOCIATION
PRIORITIES
Create conditions for the effective interaction between members of the association that provide for the exchange of ideas and opinions on the development of innovative pharmaceutical companies and the healthcare system in general.
Protect and maintain the intellectual property rights of innovative drugs.
Provide interaction between representatives of innovative pharmaceutical companies and healthcare professionals in accordance with the laws of the Russian Federation.
Represent and protect the interests of members of the Association within Government and healthcare authorities.
Unite innovative companies in the vendor community and formulate consolidated positions on the development and regulation of the industry.
Participate in the reform of existing approaches to price regulation and reimbursement of medicines.
Develop and maintain cooperation with international associations which unite innovative pharmaceutical companies.
Regimes of clinical trials data protection encourage companies to invest in pharmaceutical research in those countries where such ban is in effect. If the data exclusivity regime is violated in our country, confidence of foreign investors in the Russian market will be shattered.Vadim Kukava, Executive Director InPharma
Pilot projects must be launched now. Only then we will be able to get a fully functioning compensation program in the country by 2019.Vadim Kukava, Executive Director InPharma
The sooner patients get easy access to innovative treatments, the more lives we’ll be able to save every year.Vadim Kukava, Executive Director InPharma
Pharmaceuticals is one of the most innovative industries that often spends billions of dollars and dozens of years to develop one new moleculeVadim Kukava, Executive Director InPharma
Generally in our country diseases are treated only when they’re already in critical stages, even though everyone knows that early treatment is more effective and cheaperVadim Kukava, Executive Director InPharma
Pharmaceuticals is one of the industries that depend a lot on the protection of intellectual property because intellectual property plays a huge role in the business of innovative pharmaceutical companies.Vadim Kukava, Executive Director InPharma
If everything is reduced to the issuance of mandatory licenses for medications, investor interest in the Russian market will collapse.Vadim Kukava, Executive Director InPharma
Any cuts of the healthcare budget will have negative impact on society and the economyVadim Kukava, Executive Director InPharma
Additional budget funds will be required to include new effective drugs in the List of Vital and Essential Medicines, but it will reduce the incidence of diseases in the future and thus save the state money on treatment.Vadim Kukava, Executive Director InPharma